![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Experimental Asthma and Allergy Research, Division of Physiology, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Nitric oxide (NO) in exhaled air is a biomarker of airway inflammation. However, the role of NO in the peripheral lung is not known. The aim of this study was to determine the role of endogenous NO in antigen-induced contractions of ovalbumin (OVA)-sensitized guinea pig lung parenchyma (GPLP). The contraction in this in vitro model of the peripheral lung closely resembles the corresponding response in human airways. Cumulatively increasing concentrations (1010,000 µg/l) of OVA induced concentration-dependent contractions of the GPLP that were enhanced by the NO synthase (NOS) inhibitors N
-nitro-L-arginine (L-NOARG; 100 µM), N
-monomethyl-L-arginine (100 µM), N
-nitro-L-arginine methyl ester (100 µM), and N-(3-(aminomethyl)benzyl)acetamidine (1400W; 1 µM). The enhancement induced by L-NOARG was reversed by coadministration with the 5-lipoxygenase inhibitor (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid (BAY x1005; 3 µM), whereas coadministration of L-NOARG with the cyclooxygenase inhibitor indomethacin (10 µM) did not change the effect of L-NOARG alone. L-NOARG (100 µM) did not affect the cumulative concentration-response relations for either leukotriene (LT) D4 (0.1100 nM) or histamine (130 µM). The NO donor NONOate (0.001100 µM) was ineffective in GPLP but potently relaxed precontracted guinea pig pulmonary artery. Furthermore, L-NOARG enhanced the release of LTE4 and decreased the release of prostaglandin E2 induced by OVA. In conclusion, endogenous NO exerts an inhibitory effect on antigen-induced contractions in the peripheral lung. The action of NO apparently involves inhibition of the release of mediators rather than direct relaxation of airway smooth muscle. The findings support the belief that endogenous NO has a protective anti-inflammatory effect in the airways.
Address correspondence to: Anna-Karin Larsson, Experimental Asthma and Allergy Research, Division of Physiology, The Institute of Environmental Medicine, Karolinska Institutet, P.O. Box 287, SE-17177 Stockholm, Sweden. E-mail: anna-karin.larsson{at}imm.ki.se
This article has been cited by other articles:
![]() |
H. Maarsingh, A. B. Zuidhof, I. S. T. Bos, M. van Duin, J.-L. Boucher, J. Zaagsma, and H. Meurs Arginase Inhibition Protects against Allergen-induced Airway Obstruction, Hyperresponsiveness, and Inflammation Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 565 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Nieri, C. Martinelli, C. Blandizzi, N. Bernardini, R. Greco, C. Ippolito, M. Del Tacca, and M. C. Breschi Role of Cyclooxygenase Isoforms and Nitric-Oxide Synthase in the Modulation of Tracheal Motor Responsiveness in Normal and Antigen-Sensitized Guinea Pigs J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 648 - 656. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ihre, P. Gyllfors, L. E. Gustafsson, M. Kumlin, and B. Dahlen Early rise in exhaled nitric oxide and mast cell activation in repeated low-dose allergen challenge Eur. Respir. J., June 1, 2006; 27(6): 1152 - 1159. [Abstract] [Full Text] [PDF] |
||||